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Versatile members of the DNAJ 
family show Hsp70 dependent 
anti-aggregation activity on RING1 
mutant parkin C289G
Vaishali Kakkar1,*, E. F. Elsiena Kuiper1,2,*, Abhinav Pandey3, Ineke Braakman3 & 
Harm H. Kampinga1
Parkinson’s disease is one of the most common neurodegenerative disorders and several mutations 
in different genes have been identified to contribute to the disease. A loss of function parkin RING1 
domain mutant (C289G) is associated with autosomal-recessive juvenile-onset Parkinsonism (AR-
JP) and displays altered solubility and sequesters into aggregates. Single overexpression of almost 
each individual member of the Hsp40 (DNAJ) family of chaperones efficiently reduces parkin C289G 
aggregation and requires interaction with and activity of endogenously expressed Hsp70 s. For DNAJB6 
and DNAJB8, potent suppressors of aggregation of polyglutamine proteins for which they rely mainly 
on an S/T-rich region, it was found that the S/T-rich region was dispensable for suppression of parkin 
C289G aggregation. Our data implies that different disease-causing proteins pose different challenges 
to the protein homeostasis system and that DNAJB6 and DNAJB8 are highly versatile members of the 
DNAJ protein family with multiple partially non-overlapping modes of action with respect to handling 
disease-causing proteins, making them interesting potential therapeutic targets.
Parkinson’s disease (PD) is characterized by progressive accumulation of stable protein aggregates in the cyto-
plasm, named Lewy bodies, that lead to selective loss of dopaminergic neurons in the substantia nigra1,2. Several 
heritable forms of PD are related to mutations in the genes for α -synuclein (SNCA) and parkin (PARK2) that 
are associated with protein aggregation1,3,4. Parkin is an E3 ubiquitin ligase that plays a role in ubiquitination 
of several candidate substrate proteins and thereby targeting them for proteasomal degradation. Parkin is also 
involved in the elimination of damaged mitochondria through autophagy, called mitophagy5,6. Parkin contains 
an N-terminal ubiquitin-like (Ubl) domain, a central RING (Really Interesting New Gene) domain (RING0) 
and a C-terminal RING domain consisting of two RING finger motifs (RING1 and RING2) separated by an 
In-between-RING (IBR) domain7. A wide variety of PARK2 mutations have been found, including exon dele-
tions, duplications and triplications, missense, nonsense, and frameshift mutations8. Here, we focus on one of 
the first-reported mutations in the RING1 domain of parkin, the Cys289 to Gly (C289G) mutation, which is asso-
ciated with an autosomal-recessive form of juvenile parkinsonism (AR-JP)9,10. Besides a loss of function, the 
C289G mutation results in alterations in parkin solubility and sequestration in aggresome-like protein aggregates 
and hence might also indicate a dominant, toxic gain-of-function phenotype11–13. Indeed, expression of parkin 
mutants in Drosophila melanogaster lead to neurodegeneration and motor impairments and carrying a single 
allele with the C289G mutant is associated with a higher risk of parkinsonism14–16. Formation of C289G parkin 
aggregates are likely due to loss of a conserved cysteine in the RING domain, which impairs interaction of the 
RING2 domain with RING0 and RING1 and hence affects the more compact arrangement in the protein. This 
leads to a disrupted protein structure, which renders it misfolded and inactive17.
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Molecular chaperones play a crucial role in various ways in the prevention of aggregation of different mutant 
proteins. Heat shock proteins (HSPs) by virtue of their function as molecular chaperones act as the first line of 
defence against protein aggregation. Most HSPs recognize exposed hydrophobic regions of non-native proteins 
and hereby can prevent protein aggregation. In doing so, they not only assist in protein (re)folding but also in the 
degradation of misfolded client proteins by targeting them to the protein degradation machineries18,19. Given the 
capacity of molecular chaperones to prevent aggregation of misfolded proteins, and reminiscent of our previous 
work on polyglutamine (polyQ) aggregation20,21, they might be of use as therapeutic intervention to prevent 
aggregation of parkin C289G20,22–29. Two related members within the Hsp40 family of chaperones (the DNAJB 
subfamily), namely DNAJB6 and DNAJB8, were found to be excellent suppressors of protein aggregation in a 
polyQ disease cellular model, whilst several other members were less or not active20. DNAJB6 up-regulation in 
mouse brain delays polyQ aggregation, relieves symptoms, and prolongs lifespan30. Detailed analysis showed 
that both in vitro and in cells DNAJB6 was able to bind to polyQ containing polypeptides through an S/T rich 
stretch30 that competes with the hydrogen bonding necessary for formation of amyloid fibrils by β -hairpins31. 
In line, DNAJB6 prevents both the nucleation of Aβ peptides into amyloids and the incorporation of Aβ into 
pre-existing amyloid fibers32. Using the same cell model used for the polyQ protein aggregation, we here per-
formed a screen for DNAJ proteins that could handle parkin C289G aggregation. Unlike for polyQ aggregation, 
all cytoplasmic DNAJs were found to be almost equally effective in preventing parkin C289G aggregation and this 
activity required a functional J-domain, meaning their functionality was dependent on interaction with Hsp70 s. 
However, for the anti-aggregation activity of DNAJB6 and DNAJB8 on parkin C289G the S/T rich stretch was 
found to be dispensable, indicating that polyQ and parkin aggregation occur via distinct routes. Our data further 
show that DNAJ proteins keep parkin C289G in a soluble, degradation-competent form, thus increasing the total 
amount (but not rate) of parkin C289G being degraded.
Results
Most DNAJA and DNAJB family members efficiently reduce parkin C289G aggregation. 
Previously, we have shown that aggregation of polyQ proteins can be prevented most efficiently by DNAJB6b and 
DNAJB8, as well as DNAJB2a20, but less efficient by most other DNAJs. To test which DNAJ members are also able 
to reduce parkin C289G aggregation, HEK293 cells were transiently co-transfected with V5-tagged DNAJs and 
flag-tagged parkin wildtype (WT) or C289G mutant. Upon Triton X-100 (TX-100) lysis, most of the wild-type 
protein distributes to the TX-100 soluble fraction (Fig. 1A, lane 1 and 6), whereas parkin C289G ends up in the 
TX-100 insoluble fraction (Fig. 1A, lane 2 and 7). In addition, for parkin C289G a high molecular weight (HMW) 
smear in the TX-100 insoluble fraction of the cell lysate can be seen (Fig. 1A, lane 7), consistent with earlier work6 
and indicative of parkin C289G aggregation. In parallel, the steady state levels of parkin C289G were lower than 
that of parkin WT (Supplementary Fig. S1). Furthermore, cells expressing parkin WT show uniform distribu-
tion of the protein whilst parkin C289G shows multiple large inclusions scattered throughout the cytoplasm 
(Fig. 1B, panel 1 and 2). Co-expression of DNAJB6b and DNAJB8 as well as DNAJB2a, decreased parkin C289G 
aggregation to a similar extent (Fig. 1A, lane 8, 9 and, 10), which was always paralleled by a reduction in the 
steady state levels of parkin C289G (Supplementary Fig. S1, see also below). Inclusion formation was also equally 
effectively reduced by DNAJB2a (Fig. 1B, panel 3) and DNAJB8 (Fig. 2C, panel 1). For DNAJB2a, these data are 
in line with the findings of Rose et al. using different cell lines6. Next, other members of the DNAJA and DNAJB 
family were tested for their ability to prevent aggregation of parkin C289G. Co-expression of most DNAJs were 
found to reduce insolubilization of parkin C289G (Supplementary Fig. S2A,B). Exceptions are DNAJA3, which is 
localized to mitochondria33,34, and DNAJB9, which is normally localized to the ER33,35 and was hardly expressed 
here. The inability of these chaperones to prevent parkin C289G aggregation must be attributed to their different 
localization than parkin, which is predominantly cytosolic and forms perinuclear inclusions. The finding that all 
cytoplasmic DNAJAs and DNAJBs tested were found to be almost equally effective in preventing parkin C289G 
aggregation, differs strongly from what we found for prevention of polyQ aggregation suggesting that polyQ and 
parkin C289G requires different handling by the protein quality control (PQC) system.
A functional J-domain is critical for activity of DNAJ proteins against parkin C289G aggregation. 
To investigate the role of the different domains of DNAJ proteins in preventing parkin C289G aggregation, differ-
ent mutants of the DNAJB6b and DNAJB8 chaperones were co-transfected with parkin C289G (Fig. 2A). DNAJ 
chaperones contain a highly conserved ~70 amino-acid J-domain with a histidine-proline-aspartic acid (HPD) 
motif, which is necessary for the interaction between DNAJs and Hsp70 s36. Here, we used DNAJ mutants in 
which the histidine residue in the HPD motif was substituted by a glutamine (H/Q) leading to a J-domain that 
can no longer bind to Hsp70 s. We also used a mutant of DNAJB6b in which the entire J-domain was deleted (Δ J) 
(Fig. 2B). Mutations in the J-domain or deletion of the J-domain render the DNAJs incapable of preventing 
aggregation of parkin C289G (Fig. 2A, lane 17, 18, 21, and 24). Using DNAJB8 as a representative of DNAJ fam-
ily, we confirmed this with immunohistochemistry, showing that in cells co-transfected with the H/Q mutant of 
DNAJB8, parkin C289G still forms large inclusions. Interestingly, unlike wild type DNAJB8, the DNAJB8 H/Q 
mutant was found to co-localize with parkin C289G aggregates, suggesting that it may be trapped here due to its 
inability to interact with Hsp70 (Fig. 2C, panel 2). Together, these data imply that Hsp70 interaction is required 
for all DNAJs to prevent parkin C289G aggregation.
We used a deletion mutant of DNAJB8 that lacks the serine/threonine (S/T) rich domain (Δ SSF-SST) at the 
C-terminal (Fig. 2B). In contrast to the crucial role of this domain in the prevention of polyQ aggregation20,30, 
the Δ SSF-SST mutant fully retained its anti-aggregation activity on parkin C289G as revealed by fractionation 
(Fig. 2A, lane 22) and immunofluorescence (Fig. 2C, panel 3). Besides the J-domain and the S/T domain mutants, 
we tested a DNAJB6b mutant with a missense mutation in the G/F-rich region (F93L). This F93L mutant is 
implicated in limb-girdle muscular dystrophy and had been suggested to be slightly impaired in delaying polyQ 
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mediated aggregation37. The F93L mutant was still largely effective in preventing parkin C289G aggregation 
(Fig. 2A, lane 19), implying that this disease-causing mutation has little impact on the functional DNAJB6-Hsp70 
interaction that deals with parkin C289G aggregates. These combined data further illustrate different chaperone 
activity requirements for dealing with either polyQ or parkin C289G aggregation.
Hsp70 s are required for full prevention of parkin C289G aggregation. To further consolidate that 
DNAJs prevent aggregation of parkin C289G via an interaction with Hsp70 s, we examined whether short inter-
fering RNA (siRNA)-mediated knockdown of HSPA1A had an effect on the DNAJ mediated clearance of parkin 
C289G. Interestingly, the partial siRNA-mediated knockdown of HSPA1A alone already increases parkin C289G 
insolubilization considerably (Fig. 3A, lane 11 and 12), implying that constitutively expressed HSPA1A contrib-
utes to handling of parkin C289G to reduce its aggregation. In the siRNA-treated cells, the overexpressed DNAJs 
largely lost their ability to prevent parkin C289G aggregation. Yet, a small reduction in parkin C289G aggrega-
tion is still seen for DNAJB2a, DNAJB6b, or DNAJA1 (but not DNAJB1) (Fig. 3A, lane 14, 16, and 20 compared 
to lane 12). Under knockdown conditions more of the parkin C289G HMW smears were now detected in the 
TX-100 soluble fraction of DNAJB2a, DNAJB6b, and DNAJA1 co-expressing cells (Fig. 3A, lane 4, 6, 8, and 10), 
suggesting some Hsp70-independent actions of the DNAJs prior to parkin C289G insolubilization. When cells 
were treated with VER-155008, an adenosine-derived Hsp70 inhibitor that targets the ATPase binding domain of 
Figure 1. DNAJB2a, DNAJB6b, or DNAJB8 can prevent aggregation of parkin C289G. (A) HEK293 cells 
were transfected with flag-tagged parkin WT, flag-tagged parkin C289G, or co-transfected with flag-tagged 
parkin C289G and V5-tagged DNAJB2a, DNAJB6b, or DNAJB8. Expression of chaperones was induced with 
tetracycline. Triton X-100 (TX-100) soluble and insoluble fraction were obtained 24 hours after transfection. 
Parkin WT and C289G were assessed with anti-parkin and anti-flag antibodies on Western blot and analysed for 
parkin C289G high molecular weight species and normalised to parkin C289G (*p < 0.05;  ***p < 0.001; n > 4 
independent samples, mean ± SEM). In the TX-100 insoluble fraction, high molecular weight (HMW) species 
of parkin C289G are observed. Co-transfection with DNAJB2a, DNAJB6b, or DNAJB8 prevents formation 
of parkin C289G HMW species. Anti-parkin antibodies detect full-length parkin and an N-terminally 
truncated isoform (also removing the flag-tag), generated due to an internal start site, showing an extra band 
around 42 kDa68. The anti-flag antibodies recognize predominantly the full-length parkin protein. Expression 
of chaperones was detected with anti-V5 antibodies. GAPDH was used as a loading control for the soluble 
fraction. (B) Representative immunofluorescence pictures of cells co-transfected with flag-tagged parkin WT 
or parkin C289G (red) and V5-tagged chaperones (green). DAPI staining is shown in blue. Bar represents 
10 μ m. Parkin WT shows a diffuse pattern throughout the cytoplasm. Parkin C289G forms aggregates mainly 
concentrated into large perinuclear inclusions. Co-transfection with DNAJB2a reveals clearance of parkin 
C289G aggregates and co-localization of DNAJB2a with parkin C289G, indicated by arrowheads.
www.nature.com/scientificreports/
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Figure 2. The anti-aggregation activity of DNAJ chaperones is dependent on the J-domain, not on the SSF-
SST domain. (A) Aggregation of parkin C289G is prevented when co-transfected with DNAJB2a, DNAJB6b, 
DNAJB8, or DNAJB1. Mutations in the J-domain of the chaperones (H/Q) and deletion of the J-domain as 
a whole (Δ J), results in the loss of prevention of aggregation of parkin C289G. DNAJB6b with a mutation 
in the G/F-rich region (F93L) retains its anti-aggregation activity. Deletion of the SSF-SST domain (Δ SSF-
SST) of DNAJB8 does not affect its ability to prevent aggregation. Blots are analysed for parkin C289G high 
www.nature.com/scientificreports/
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all Hsp70 s38, similar results were observed (Fig. 3B). These data suggest that DNAJs are capable in maintaining 
parkin C289G in a soluble state when Hsp70 s are depleted but that Hsp70 s are required for full prevention of 
parkin C289G aggregation.
From the above results so far, parkin C289G appears to be a substrate for the Hsp70 machine, in which upreg-
ulation of different DNAJs can enhance the cellular capacity for its degradation by keeping it more soluble, as long 
as sufficient Hsp70 activity is available (Figs 1, 2 and 3). Yet, upregulation of different members of the Hsp70 fam-
ily alone did not result in reduced parkin C289G aggregation (Supplementary Fig. S3A, lanes 12–18) ), suggesting 
that other factors are actually rate limiting. A minimal Hsp70 machine contains, besides DNAJs and HSPAs, also 
nucleotide exchange factors (NEFs)33. NEFs are a heterologous group of co-factors required for the dissociation 
of the substrate from HSPA and may also - in part - determine the fate of the substrate33, like HSPH2, which is 
able to remodel the Hsp70 machine to efficiently disaggregate aggregated proteins, and BAG339, which has been 
implicated in dealing with aggregation of polyQ proteins. However, neither overexpression of the cytosolic NEFs 
(HSPH1, HSPH2, or HSPH3) (Supplementary Fig. S3B) nor the overexpression of the BAG family members 
(BAG1, BAG3, and BAG4) (Supplementary Fig. S3C) could reduce the aggregation of parkin C289G. So, within 
the background of endogenous expression levels of HSPs in HEK293 cells, overexpression of DNAJs seems the 
most effective way (i.e. rate limiting) to increase the efficiency of the Hsp70 machine to prevent aggregation of 
parkin C289G.
DNAJs keep parkin C289G in a soluble, degradation-competent form. To further examine how 
DNAJs affect parkin C289G aggregation, we performed pulse-chase experiments to monitor the fate of newly 
synthesized parkin. In the TX-100 soluble fraction, parkin C289G is more rapidly degraded than parkin WT 
(Fig. 4A,B), as shown before11 and indicative that it is recognized by the PQC system as misfolded. The expression 
of DNAJB8 (a representative of DNAJ family effective against parkin C289G aggregation) does not accelerate 
the rate of degradation of parkin WT or parkin C289G (Fig. 4C). However, DNAJB8 clearly reduced the fraction 
of parkin C289G (but not WT) that becomes TX-100 insolubilized in a 2-hour chase (Supplementary Fig. S4), 
meaning that in the presence of DNAJB8 more parkin C289G is kept competent for degradation over time, 
which is consistent with the reduced steady state levels of parkin C289G in cells co-expressing DNAJ proteins 
(Supplementary Fig. S1).
Discussion
In the current study we show that, when upregulated in cells, all cytosolic members of the DNAJA and DNAJB 
subfamilies can suppress parkin C289G aggregation in an Hsp70 dependent manner. Hsp70 inhibition increased 
parkin C289G aggregation, even under conditions when DNAJs are overexpressed, but upregulation of HSPAs 
could not prevent an increase in parkin C289G aggregation. Further, overexpression of the cytosolic NEFs 
(HSPH1, HSPH2, HSPH3, BAG1, BAG3, and BAG4) did not lead to reduced parkin C289G aggregation. 
Comparing our current observations regarding the role of various chaperones on parkin C289G aggregation to 
our previous studies20,21,39 on aggregation of polyQ containing proteins, performed in the same cell model, reveals 
a number of intriguing features. First, the DNAJB6b and DNAJB8 chaperones that we previously identified as the 
most potent, but largely Hsp70-independent, suppressors of polyQ aggregation20, can also inhibit parkin C289G 
aggregation but do now fully depend on a functional Hsp70 machine. Second, the S/T-rich region in DNAJB6 
and DNAJB8 that is crucial for preventing polyQ aggregation20,30, is dispensable for their protective action on 
parkin C289G. Third, DNAJB8 can keep parkin C289G in a degradation competent form, hereby reducing insol-
ubilized material and increasing clearance of the mutant protein. This implies that different aggregation-prone, 
disease-causing proteins pose different challenges to the PQC systems and require specific chaperones for their 
handling and hence also highlight certain degree of functional differentiation between various families of HSP 
proteins.
The substantial differences between the chaperone requirements for two different aggregation-prone, 
disease-causing proteins can be explained by the fact that the aggregates caused by the two mutant proteins 
have different biochemical properties as revealed by detergent solubility. Whilst parkin C289G aggregates are 
TX-100 insoluble but largely SDS soluble (ref. 18, this report), polyQ aggregates are both TX-100 and SDS insol-
uble20,40–43. Further, the morphology of the aggregates is more dispersed for parkin C289G (ref. 18, this report) 
whilst polyQ proteins form more amyloid like inclusions20,40. Finally, whereas the Cys289 to Gly mutation in the 
RING1 domain of parkin leads to a disruption of the zinc coordination of the protein and thus to protein misfold-
ing44, polyQ expansions within a full length huntingtin or ataxin-3 are not exposed and the full length proteins 
are not misfolded to an extent that they render the protein a target for accelerated degradation45,46. Rather, the 
full length polyQ expansion does not initiate aggregation until it is fragmented by the action of proteases46–49 
molecular weight species and normalised to parkin C289G (*p < 0.05;  ***p < 0.001; n > 4 independent samples, 
mean ± SEM). (B) Schematic overview of DNAJB1, DNAJ2a, DNAJB6, and DNAJB8 and the mutants.  
(C) Representative immunofluorescence pictures of cells co-transfected with flag-tagged parkin C289G (red) 
and V5-tagged chaperones (green). DAPI staining is shown in blue. Bar represents 10 μ m. Co-transfection with 
DNAJB8 shows a reduction in parkin C289G aggregates and co-localization of DNAJB8 with parkin C289G, 
indicated by arrowheads. Co-transfection with DNAJB8 H/Q still shows formation of parkin C289G aggregates 
mainly concentrated into large perinuclear inclusions, indicated by arrowheads. Parkin C289G and DNAJB8 
H/Q co-localize but aggregate formation is not prevented. Co-transfection with DNAJB8 Δ SSF-SST reveals 
clearance of parkin C289G aggregates and in occasional small aggregations co-localization of DNAJB8  
Δ SSF-SST with parkin, indicated by arrowheads.
www.nature.com/scientificreports/
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Figure 3. The anti-aggregation activity of DNAJ chaperones is dependent on Hsp70 s. (A) Knockdown of 
HSPA increases levels of TX-100 soluble and insoluble parkin C289G. In cells co-transfected with DNAJs, the 
HMW smear is still formed, indicating that DNAJs lose their ability to prevent parkin C289G aggregation. 
However, a reduction in the smear can be observed when parkin C289G is co-transfected with DNAJB2a, 
DNAJB6b, or DNAJA1 (not DNAJB1) compared to parkin C289G alone. There is an increase in the TX-100 
soluble fraction when co-transfected with DNAJs, indicating more soluble parkin C289G under conditions 
of knockdown of HSPAs and suggesting some Hsp70-independent actions of the DNAJs prior to parkin 
insolubilization. (B) Hsp70 s are inhibited with VER-155008, an adenosine-derived HSPA inhibitor that targets 
the ATPase binding domain. Similar results are observed as in panel A.
www.nature.com/scientificreports/
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or has undergone conformational changes such that flanking sequences open up or align the polyQ stretch for 
β -hairpin-mediated nucleation31,50,51. For the latter, we recently showed the S/T-rich region in DNAJB6 to be 
the crucial binding motif30, which is dispensable for its action on parkin C289G. Similar to DNAJ family mem-
bers, differences were observed within the HSPB family of small HSPs: HSPB7 was the most effective in pre-
venting polyQ aggregation and HSPB1 was ineffective21, while HSPB1 was very effective in preventing parkin 
C289G aggregation52. Finally, the mode of action of DNAJB6 and DNAJB8, which effectively reduced both types 
of aggregates, was different for polyQ proteins (largely Hsp70 independent) and parkin C289G (largely Hsp70 
dependent). So, although several neurodegenerative diseases share protein aggregation as a common feature, 
Figure 4. DNAJB8 keeps parkin C289G more in a soluble, degradation competent form. (A) Reduced 
autoradiograms of pulse chase labelling of flag-parkin. HeLa cells transfected with parkin WT, parkin C289G 
with or without DNAJB8 were pulse labeled with [35S]-labeled cysteine and methionine for 10 minutes 
and chased for the indicated time periods. Following detergent lysis, parkin WT and parkin C289G were 
immunoprecipitated with monoclonal flag antibody. Reduced samples were resolved by 10% SDS-PAGE.  
(B) Detergent soluble parkin WT or parkin C289G was quantified by phosphoimaging and data was plotted as a 
semi-log graph(n = 3 independent samples, mean ± SD).
www.nature.com/scientificreports/
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the characteristics of the different aggregation-prone proteins impose a substantially different challenge on the 
cellular PQC system29,53.
We have previously shown that Hsp70 members are rather ineffective in preventing polyQ aggregation in 
HEK293 cells20. In contrast, in the same cells we now find that the activity and level of Hsp70 does matter for 
parkin C289G aggregation. Knocking down HSPA1A or pharmacological inhibition of “all” HSP70 s substantially 
aggravated parkin C289G aggregation (Fig. 3A,B). Yet, overexpression of the HSPA members or enhancing the 
ATPase activity of “all” Hsp70 s using the drug SW0254,55 did not lead to a reduction in parkin C289G aggregation 
(Supplementary Fig. S3A; Fig. S5), unlike what was found for other substrates, like the Alzheimer related proteins 
tau and amyloid-β 54,55. These data show the differential effects of Hsp70 levels itself; they are not rate limiting in 
case of polyQ, are required but constitutively sufficiently expressed in case of parkin C289G, or required and rate 
limiting in case of tau. Moreover, overexpression of some HSP70 s (HSPA1L and HSPA9) even enhanced parkin 
C289G aggregation (Supplementary Fig. S3A). The latter is in line with the findings of the Hasson paper where 
knockdown of HSPA1L was found be associated with reduced parkin aggregation56. Together, this not only sup-
ports our conclusions that different aggregation-prone proteins require different chaperone handling29, but also 
suggests that besides DNAJs and NEFs, also the diverse members of the Hsp70 family can determine the func-
tional specificity of Hsp70 machines33. Although this may seem striking giving the large sequence identity, the 
similar peptide recognition motifs, and biochemical activity that these Hsp70 members are assumed to have57,58, 
work by the Frydman group already suggested that distinct Hsp70 members may act in different chaperone net-
works, one predominantly dealing with protein translation and one with (environmental) stress59. Further sup-
port for functional differentiation between the Hsp70 family members was provided by the group of Jäättelä60 and 
our own findings that e.g. HSPA6 was largely ineffective in refolding unfolded substrates61.
What is the mechanism through which all the DNAJs can suppress parkin C289G aggregation? For DNAJB2a, 
it has been suggested that prevention of parkin C289G aggregation was associated with restoring its function in 
mitophagy6, implying that such anti-aggregation effects are associated with a DNAJ/HSP70 assisted folding of the 
misfolded mutant. We indeed confirmed that parkin C289G shows a loss of function phenotype, as it no longer 
associated with mitochondria upon cellular treatment with the mitochondrial uncoupler CCCP (Supplementary 
Fig. S6A, panel 3 and 4; Fig. S6B). However, co-expression of DNAJBs did not restore this loss of function pheno-
type (Supplementary Fig. S6A, panel 5–7). The apparent difference between our data and those of the Cheetham 
group6 might be explained by the fact that the cells we used in our study (HeLa) express near to no endoge-
nous wild type parkin, whilst the SK-N-SH cells (used by the Cheetham group) do62. This could imply that the 
aggregating mutant has dominant negative effects on the wild-type protein and that preventing such aggregation 
alleviates this effect to some extent. So, rather than refolding the mutant, our data suggest that DNAJs can main-
tain parkin C289G in a degradation-competent state. Whilst this does not accelerate the rate of mutant parkin 
degradation (Fig. 4A), the amount of parkin C289G that is degraded is increased in the presence of additional 
DNAJ protein expression (Fig. 4B), resulting in lower levels of parkin C289G (Fig. 1; Supplementary Fig. S1). This 
effect was not seen for parkin WT levels (Supplementary Fig. S1), indicating that this is related to the specific 
recognition of the misfolded species. The effect on parkin C289G was also lost when co-expressing the various 
DNAJ H/Q mutants that cannot interact with Hsp70 (Fig. 2), implying that Hsp70 is required for this action. 
Furthermore, as revealed by our western analysis, parkin C289G is present as a high molecular weight smear in 
the TX-100-insoluble fraction, consistent with other studies that the mutant is polyubiquitinated11,63, but has 
aggregated before being degraded. It is interesting to note that DNAJs were also still slightly effective under 
conditions of HSPA1A knockdown and that this was paralleled by an increase of high molecular weight species 
of parkin C289G in the TX-100 soluble fraction (Fig. 3A,B). Based on this, we propose a model for the handling 
of parkin C289G by the Hsp70 machinery (Fig. 5) in which the DNAJs primarily and transiently bind misfold-
ing and aggregating polypeptides of parkin C289G, keeping them soluble for degradation (holding activity) via 
Figure 5. Model for the interaction of DNAJs with HSPAs for the handling of parkin C289G. DNAJs can 
primarily and transiently bind with the misfolded and ubiquitinated polypeptides of parkin C289G at an early 
stage (holding activity). In this way parkin C289G can be kept soluble and can be delivered via the Hsp70 s 
(HSPA1A and/or HSPA14) for degradation. When DNAJs are not sufficiently present or when Hsp70 s are 
depleted or inhibited, protein degradation fails and parkin C289G forms aggregates.
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transfer by Hsp70 s. The holding activity of DNAJB1 may be the weakest of the ones tested, explaining why it lacks 
any effect when it when Hsp70 is depleted or inhibited.
Overall, our data further strengthens the concept that DNAJ proteins may be an attractive target in preven-
tion of aggregation of disease-causing proteins. Furthermore, DNAJ upregulation does not seem to affect the 
general chaperone network (data not shown), which may have adverse effects64, and may be targeted for strong 
and specific interventions in various protein aggregation diseases. It was even more striking that DNAJB6, which 
we already identified as suppressor of amyloid-beta in vitro32, polyQ aggregation in vitro65, in cells20, and mice 
in vivo30 was also effective in suppressing parkin C289G aggregation in cells (this report), albeit with differential 
domain structure requirement. This suggests that DNAJB6 is a central and versatile player in PQC and thus 
attractive target in several neurodegenerative diseases including in Parkinson’s disease.
Materials and Methods
Cell line, cell culture, and transient transfections. HEK293 stably expressing the tetracycline (tet) 
repressor (Flp-In T-REx HEK293, Invitrogen) were grown in DMEM (GIBCO) plus 10% FCS (Greiner Bio-one), 
100 units/ml penicillin, and 100 mg/ml streptomycin (Invitrogen), and for Flp-In TREx HEK293 cells, 5 mg/ml 
Blasticidine (Invitrogen). For transient transfections, cells were grown to 70–80% confluence in 35 mm diameter 
dishes coated with 0.001% poly-L-lysine (Sigma) and/or on coated coverslips for confocal microscopy analyses. 
Cells were transfected with Lipofectamine (Invitrogen) according to the manufacturer’s instructions with a 1:1 
ration of parkin and molecular chaperones. When transfecting with molecular chaperones tetracyclin was added 
to the medium. For transfection with siRNA, Lipofectamine2000 (Invitrogen) was used according to the manu-
facturer’s protocol before transfection with Lipofectamine. For inhibition of Hsp70 activity, VER-155008 (Sigma) 
at a 40 uM concentration was added to cells immediately after transfection and then cells were further incubated 
for 8 hours.
Gene cloning and generation of mutants. Information about the (construction of) the chaperone plas-
mids used in this study is described in Hageman et al.20. Information on the plasmid used for parkin is described 
in Ardley et al.66.
Protein extraction to obtain soluble and insoluble fractions for Western blotting. 24 hours after 
transfection cells were washed once in cold phosphate-buffered saline (PBS) and lysed in 200 μ L 1% Triton X-100 
in PBS, containing 1% complete protease inhibitor cocktail for mammalian cells (PIC) (Roche Applied Science) 
for 15 minutes on ice. Cell lysates were scraped and centrifuged at 14000 rpm (Eppendorf, rotor F45-30-11) for 
15 minutes at 4 °C. Supernatants were transferred to eppendorfs (Triton X-100 soluble fraction). Pellets were 
resuspended in 200 μ L 1% SDS in PBS, containing 1% PIC and sonicated before centrifugation at 14000 rpm 
(Eppendorf, rotor F45-30-11) for 15 minutes at 4 °C. Supernatants were collected (Triton X-100 insoluble frac-
tion). Samples were diluted in 2x SDS-sample loading buffer with 20% β -mercaptoethanol (Sigma) to a final 
concentration of 1x and were left unboiled. Samples were used immediately or kept frozen at − 20 °C.
Western blot analysis. From the unboiled samples, 10 μ l of soluble fraction, 10 μ l of pellet fraction and 3 μ l 
PageRuler Prestained Protein Ladder (Thermo Scientific) were loaded on 12.5% SDS-PAGE gels. SDS-PAGE was 
performed using the BioRad Mini-PROTEAN 3 system. After SDS-PAGE, proteins were transferred to nitro-
cellulose membranes by wet electrotransfer with the BioRad Mini-PROTEAN 3 system. The transfer was car-
ried out for 1.5 hour at 100 V. To prevent non-specific protein binding, membranes were incubated in 5% (w/v) 
non-fat dried milk in PBS-Tween (PBS-T) for one hour at room temperature. Membranes were washed three 
times 5 minutes in PBS-T and incubated for at least one hour with mouse anti-parkin antibody (Cell Signaling 
Technology) at a 1:1000 dilution, mouse anti-flag antibody (Sigma-Aldrich) at a 1:2000 dilution, mouse anti-V5 
antibody (Invitrogen) at a 1:5000 dilution, mouse anti-Hsp70 (Enzo Life Sciences) at a 1:5000 dilution, and mouse 
anti-GAPDH (Fitzgerald) at 1:10000 dilution. Membranes were washed three times 10 minutes and incubated for 
one hour in anti-mouse HRP-conjugated secondary antibody (GE Healthcare) at an 1:5000 dilution in PBS-T. 
After incubation, membranes were washed three times 10 minutes in PBS-T and enhanced chemiluminscence 
detection was performed using the ECL Western Blotting substrate kit (Thermo Scientific) using 750 μ L solu-
tion 1, mixed with 750 μ L solution 2 per membrane. Quantifications were performed using Gelpro software 
and graphs were generated using GraphPad prism. Statistical significance was analysed using an independent 
Student’s t-test, p < 0.05 was considered statistically significant. Values are expressed as the mean ± SEM.
Immunolabeling and microscopy. 24 hours after transfection, indirect immunofluorescence of the 
flag-tag and the V5-tag was performed to detect the exogenously expressed parkin and chaperones. Cells were 
fixed with 3.7% formaldehyde for 15 minutes, washed three times 5 minutes with PBS, permeabilized with 0.2% 
Triton-X100 and blocked 10 minutes with 0.1% glycine and 30 minutes with 0.5% BSA in PBS. Incubation with 
rabbit anti-V5 antibody (Sigma-Aldrich) and mouse anti-flag antibody (Sigma- Aldrich) at a 1:200 dilution 
in PBS-T was performed overnight at 4 °C. Cells were washed three times 5 minutes with PBS-T followed by 
a 1 hour incubation with Alexa Fluor 488 anti-rabbit (Invitrogen) and Alexa 594 anti-mouse (Invitrogen) sec-
ondary antibodies at a 1:1500 dilution in PBS-T. To visualize nuclei, cells were stained 10 minutes with 0.2 μ g/ml 
4’,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific). Cover slips were mounted in Citifluor (Agar 
Scientific). Images of flag, V5 and DAPI fluorescence were obtained using a Leica microscope (Leica DM6000 M) 
with a 63X oil lens. The captured images were processed using Leica Software and Adobe Photoshop CS6.
Pulse-chase analysis and immunoprecipitation. HeLa cells, approximately 24 hours post-transfection, 
were used for the pulse-chase analysis, which was carried out as described before67. Briefly, cells were pulse labeled 
for 10 minutes with 55 μ Ci/35 mm dish of Express 35S protein labelling mix (Perkin Elmer). The chase was carried 
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out with excess cold cysteine and methionine at indicated times. After the chase, cells were lysed in ice-cold lysis 
buffer (0.5% Triton X-100 in 20 mM MES, 30 mM Tris-Cl pH 7.5, 100 mM NaCl) containing 1 mM PMSF, and 
10 μ g/ml each of chymostatin, leupeptin, antipain and pepstatin. Following pelleting of nuclei, supernatant was 
transferred to Protein-G sepharose beads (GE Healthcare) that had been preincubated for one hour at 4 °C with 
monoclonal anti-flag antibody (Sigma). After overnight immunoprecipitation, immunoprecipitates were washed 
twice at room temperature with lysis buffer for 10 minutes. The immunoprecipitates were resuspended in 10 mM 
Tris-Cl and 1 mM EDTA, pH 6.8 before adding 2x concentrated sample buffer (final concentrations 200 mM 
Tris-Cl pH 6.8, 3% SDS, 10% glycerol, 1 mM EDTA, 0.004% bromophenol blue, 25 mM DTT). Samples were 
heated for 5 minutes at 95 °C and analyzed using 10% SDS-PAGE. Dried gels were exposed to Phosphorimager 
screens and analyzed by Typhoon FLA 7000 (GE Healthcare). Quantifications were performed using ImageQuant 
TL7.0 software (GE Healthcare) and the graph was generated using GraphPad prism. Figures were obtained by 
exposing the dried gels to Carestream Kodak MR BioMax films.
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